Pediatric Malignancies. Neuroblastoma, Wilm's Tumor, Hepatoblastoma, Rhabdomyosarcoma, and Sacroccygeal Teratoma.

Surgical Clinics of North America

Volumn 92, Issue 3, 2012, Pages 745-767

  Davenport, Katherine P ^a   Blanco, Felix C ^a   Sandler, Anthony D ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Hepatoblastoma; Neuroblastoma; Pediatric malignancies; Rhabdomyosarcoma; Sacrococcygeal teratoma; Wilm's tumor

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IRINOTECAN; ISOTRETINOIN; MELPHALAN; TOPOTECAN;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DISTANT METASTASIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; HEPATOBLASTOMA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INCISION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LAPAROSCOPIC SURGERY; LIVER RESECTION; LIVER TRANSPLANTATION; LONG TERM CARE; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PEDIATRICS; PHYSICAL EXAMINATION; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; SACROCOCCYX TERATOMA; SURGICAL APPROACH; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE; WHOLE BODY RADIATION;

CHILD; COMBINED MODALITY THERAPY; HEPATOBLASTOMA; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; NEUROBLASTOMA; PROGNOSIS; RHABDOMYOSARCOMA; SACROCOCCYGEAL REGION; TERATOMA; WILMS TUMOR;

EID: 84861009918     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2012.03.004     Document Type: Review

References (52)

1. Woods W.G., Gao R.N., Shuster J.J., et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002, 346(14):1041-1046.
2. Navalkele P., O'Dorisio M.S., O'Dorisio T.M., et al. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 2011, 56(1):50-57.
3. Thiele C.J. Neuroblastoma. Human cell culture 1998, 21-53. Kluwer Academic Publishers, Lancaster (United Kingdom). J. Masters (Ed.).
4. Shuangshoti S., Shuangshoti S., Nuchprayoon I., et al. Natural course of low risk neuroblastoma. Pediatr Blood Cancer 2012, 58:690-694.
5. Gilbert F., Balaban G., Moorhead P., et al. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet 1982, 7(1):33-42.
6. Nemecek E.R., Sawin R.W., Park J. Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol 2003, 25(2):159-162.
7. Monclair T., Brodeur G.M., Ambros P.F., et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009, 27(2):298-303.
8. Kushner B.H., LaQuaglia M.P., Kramer K., et al. Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol 2004, 26:35-39.
9. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11(8):1466-1477.
10. Cohn S.L., Pearson A.D., London W.B., et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009, 27(2):289-297.
11. Brodeur G.M., Maris J.M. Neuroblastoma. Principles and practice of pediatric oncology 2006, 933-970. Lippincott Williams & Wilkins, Philadelphia. 5th edition. P.A. Pizzo, D.G. Poplack (Eds.).
12. London W.B., Castleberry R.P., Matthay K.K., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005, 23(27):6459-6465.
13. Kostyrka B., Li J., Soundappan S.V., et al. Features and outcomes of neonatal neuroblastoma. Pediatr Surg Int 2011, 27(9):937-941.
14. Xu Y., Wang J., Peng Y., et al. CT characteristics of primary retroperitoneal neoplasms in children. Eur J Radiol 2010, 75(3):321-328.
15. 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011, 56(7):1041-1045.
16. Hussain H.K., Kingston J.E., Domizio P., et al. Imaging-guided core biopsy for the diagnosis of malignant tumors in pediatric patients. Am J Roentgenol 2001, 176(1):43-47.
17. Park J.R., Scott J.R., Stewart C.F., et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group Study. J Clin Oncol 2011, 29(33):4351-4357.
18. Berthold F., Hero B., Kremens B., et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003, 197(1-2):11-17.
19. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341(16):1165-1173.
20. International Pediatric Endosurgery Group IPEG guidelines for the surgical treatment of adrenal masses in children. J Laparoendosc Adv Surg Tech A 2010, 20(2):vii-vix.
21. Hollwarth M.E. Wilms' tumor. Pediatric surgery: diagnosis and management 2009, 709-715. Springer, Heidelberg (Germany). P. Puri, M. Hollworth (Eds.).
22. Shamberger R.C. Renal tumors. Ashcraft's pediatric surgery 2010, 853-871. WB Saunders, Philadelphia. 5th edition. G.W. Holcomb, J.P. Murphy, D.J. Ostlie (Eds.).
23. Vieira C., Leite M.T., Ribeiro R.C., et al. Renal tumor and trauma: a pitfall for conservative management. Int Braz J Urol 2011, 37(4):514-518.
24. Levitt G. Renal tumours: long-term outcome. Pediatr Nephrol, in press.
25. Paran T.S., La Quaglia M.P. Hepatic tumors in childhood. Pediatric surgery: diagnosis and management 2009, 727-732. Springer, Heidelberg (Germany). P. Puri, M. Hollworth (Eds.).
26. Andrews W.S. Lesions of the liver. Ashcraft's pediatric surgery 2010, 903-909. WB Saunders, Philadelphia. 5th edition. G.W. Holcomb, J.P. Murphy, D.J. Ostlie (Eds.).
27. Zimmerman A. The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer 2005, 11:1503-1514.
28. Roebuck D.J., Aronson D., Clapuyt P., et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2007, 17:123-132.
29. Aronson D.C., Schnater J.M., Staalman C.R., et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005, 23(6):1245-1252.
30. Malogolowkin M.H., Katzenstein H.M., Meyers R.L., et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. J Clin Oncol 2011, 29(24):3301-3306.
31. Reynolds M., Douglass E.C., Finegold M., et al. Chemotherapy can convert unresectable hepatoblastoma. J Pediatr Surg 1992, 27(8):1080-1083.
32. Xianliang H., Jianhong L., Xuewu J., et al. Cure of hepatoblastoma with transcatheter arterial chemoembolization. J Pediatr Hematol Oncol 2004, 26(1):60-63.
33. Malogolowkin M.H., Stanley P., Steele D.A., et al. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 2000, 18(6):1279-1284.
34. Perilongo G., Brown J., Shafford E., et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000, 89(8):1845-1853.
35. Pritchard J., Brown J., Shafford E., et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach-results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000, 18(22):3819-3828.
36. Tiao G.M., Bobey N., Allen S., et al. The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005, 146:204-211.
37. Tsay P.K., Lai J.Y., Yang C.P., et al. Treatment outcomes for hepatoblastoma: experience of 35 cases at a single institution. J Formos Med Assoc 2011, 110(5):322-325.
38. Li J.P., Chu J.P., Yang J.Y., et al. Preoperative transcatheter selective arterial chemoembolization in treatment of unresectable hepatoblastoma in infants and children. Cardiovasc Intervent Radiol 2008, 6:1117-1123.
39. Schnater J.M., Aronson D.C., Plaschkes J., et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002, 94:1111-1120.
40. Schnater J.M., Kohler S.E., Lamers W.H., et al. Where do we stand with hepatoblastoma? a review. Cancer 2003, 98(4):668-678.
41. Merchant M.S., Mackall C.L. Current approach to pediatric soft tissue sarcomas. Oncologist 2009, 14(11):1139-1153.
42. Kapoor G, Das K. Soft tissue sarcomas in children. Indian J Pediatr, in press.
43. Carachi R. [Soft tissue sarcoma]. Pediatric surgery: diagnosis and management 2009, 717-724. Springer, Heidelberg (Germany). P. Puri, M. Hollworth (Eds.).
44. Zhao M., Feng C., Wang J.W., et al. Zhongguo Dang Dai Er Ke Za Zhi 2011, 13(8):657-660. [in Chinese].
45. Gucciardo L., Uyttebroek A., De Weyer I., et al. Prenatal assessment and management of sacrococcygeal teratoma. Prenat Diagn 2011, 31(7):678-688.
46. Warner B. Pediatric surgery. Sabiston textbook of surgery, the biologic basis of modern surgical practice 2008, 2080-2089. Saunders, Philadelphia. 18th edition. C. Townsend, R. Beauchamp, M. Evers (Eds.).
47. Barakat M.I., Abdelaal S.M., Saleh A.M. Sacrococcygeal teratoma in infants and children. Acta Neurochir (Wien) 2011, 153(9):1781-1786.
48. Laberge J., Puligandla P., Shaw K. Teratomas, dermoids, and other soft tissue tumors. Ashcraft's pediatric surgery 2010, 915-935. WB Saunders, Philadelphia. 5th edition. G.W. Holcomb, J.P. Murphy, D.J. Ostlie (Eds.).
49. Paran T.S., Puri P. Sacrococcygeal teratoma. Pediatric surgery: diagnosis and management 2009, 697-701. Springer, Heidelberg (Germany). P. Puri, M. Hollworth (Eds.).
50. Smithers C.J., Javid P.J., Turner C.G., et al. Damage control operation for massive sacrococcygeal teratoma. J Pediatr Surg 2011, 46(3):566-569.
51. Solari V., Jawaid W., Jesudason E.C. Enhancing safety of laparoscopic vascular control for neonatal sacrococcygeal teratoma. J Pediatr Surg 2011, 46(5):e5-e7.
52. Le L.D., Alam S., Lim F.Y., et al. Prenatal and postnatal urologic complications of sacrococcygeal teratomas. J Pediatr Surg 2011, 46(6):1186-1190.